Moderna, Inc. splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was COVID19 at $1.8 billion, 93% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,228
|
1,944
|
3,236
|
6,848
|
19,263
|
18,471
|
803
|
60
|
135
|
| Product Sales |
—
|
—
|
—
|
6,671
-63.8%
share 97.4%
|
18,435
+4.3%
share 95.7%
|
17,675
+8737.5%
share 95.7%
|
200
share 24.9%
|
—
|
—
|
| COVID19 |
—
|
1,810
-41.3%
share 93.1%
|
3,084
-53.8%
share 95.3%
|
6,671
-63.8%
share 97.4%
|
18,435
share 95.7%
|
—
|
—
|
—
|
—
|
| Stand Ready Manufacturing Revenue |
—
|
80
share 4.1%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Collaboration Arrangement |
—
|
—
|
—
|
—
|
—
|
61
-17.6%
share 0.3%
|
74
+54.2%
share 9.2%
|
48
share 80.0%
|
—
|
| Grant |
—
|
—
|
37
-60.6%
share 1.1%
|
94
-75.8%
share 1.4%
|
388
-47.2%
share 2.0%
|
735
+38.9%
share 4.0%
|
529
+4308.3%
share 65.9%
|
12
share 20.0%
|
—
|
| Collaboration Arrangement Including Arrangements With Affiliate |
—
|
13
-72.9%
share 0.7%
|
48
-42.2%
share 1.5%
|
83
-81.1%
share 1.2%
|
440
+621.3%
share 2.3%
|
61
-17.6%
share 0.3%
|
74
+54.2%
share 9.2%
|
48
share 80.0%
|
—
|
| License And Royalty |
—
|
11
-73.8%
share 0.6%
|
42
share 1.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
| RSV |
—
|
8
-68.0%
share 0.4%
|
25
share 0.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MRNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1682852
- Former names
- Moderna Therapeutics, Inc. (until Aug 24, 2016)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.